Similar articles

• The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.

  Michael M, Hedley D, Oza A, Feld R, Pintilie M, Goel R, Maroun J, Jolivet J, Fields A, Lee IM, Moore MJ. Michael M, et al. Clin Colorectal Cancer. 2002 Aug;2(2):93-101. doi: 10.3816/CCC.2002.n.015. Clin Colorectal Cancer. 2002. PMID: 12453323 Clinical Trial.
• Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.

  [No authors listed] [No authors listed] Clin Colorectal Cancer. 2002 Aug;2(2):78-80. doi: 10.1016/s1533-0028(11)70508-4. Clin Colorectal Cancer. 2002. PMID: 12453320 Clinical Trial. No abstract available.
• N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.

  Goldberg RM. Goldberg RM. Clin Colorectal Cancer. 2002 Aug;2(2):81. doi: 10.1016/S1533-0028(11)70509-6. Clin Colorectal Cancer. 2002. PMID: 12453321 Clinical Trial. No abstract available.
• [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].

  Guan ZZ. Guan ZZ. Zhonghua Zhong Liu Za Zhi. 2006 Sep;28(9):718-9. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17274384 Review. Chinese. No abstract available.
• Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.

  Fisher MD. Fisher MD. Clin Colorectal Cancer. 2001 Aug;1(2):85-6. doi: 10.1016/S1533-0028(11)70542-4. Clin Colorectal Cancer. 2001. PMID: 12445365 Review. No abstract available.